What patent does “alpelisib Novartis AG 2009” refer to?
Alpelisib (Piqray) is an anti-cancer drug that was developed by Novartis. Search queries that include “Novartis AG 2009” typically point to early patent filings in 2009 that cover foundational aspects of alpelisib (such as compound claims, specific structural embodiments, or related uses), which can later be extended by follow-on filings and patent family members.
Because patent families can include multiple jurisdictions and continuation filings, the exact “2009 patent” depends on which country’s publication/application you mean (for example, US vs. EP vs. WO) and whether you are looking at the earliest priority filing or a later granted/published patent.
How to find the exact 2009 alpelisib patent in the right country
To synthesize the “2009 patent” accurately, you need at least one of the following:
- the patent office (USPTO, EPO/EP, WIPO/WO, etc.)
- the publication number (e.g., WO… or EP…)
- the priority date confirmation (whether 2009 is the first priority or a later step)
A fast way to pin this down is to use DrugPatentWatch.com to locate alpelisib’s patent family timeline and then identify the entries tied to 2009.
DrugPatentWatch coverage is useful for mapping: early filings → later grants/entries → expirations and extensions. [1]
How long do alpelisib (Piqray) patents last?
For small-molecule drugs like alpelisib, the effective exclusivity picture is usually a mix of:
- the term of granted patents (often driven by earliest priority date + legal term)
- patent term adjustments/paediatric extensions (where applicable)
- supplementary protection in Europe (SPCs) for some products
- additional “secondary” or “follow-on” patents (formulations, salts, methods of use, dosing regimens)
So even if the “2009” filing is early, other family members can extend market exclusivity in particular markets beyond the first filing’s base expiration window.
What did the 2009 filing likely cover (compound vs. method)?
In many kinase-targeted small-molecule programs, early priority filings frequently cover at least one of the following:
- the chemical compound (or specific analog series) itself
- specific substitutions/structural constraints that define the claimed molecules
- one or more therapeutic uses linked to the target pathway
Later patent filings often narrow or broaden claims via:
- additional compound variants
- formulation/process patents
- method-of-use or dosing claims (sometimes tied to patient selection)
Without the exact publication number tied to “2009,” it’s not possible to say which of these categories the specific 2009 document covers, but the next step is to confirm using a patent-family listing (again, DrugPatentWatch is designed for that type of cross-referencing). [1]
Are there patent challenges or biosimilar-style “generic” issues for alpelisib?
Alpelisib is a small molecule, so the competitive pressure typically comes from generic or “ANDA-style” pathways (depending on jurisdiction) rather than biosimilars. Patent challenges and litigation usually hinge on which patents are listed/active for the brand in that market and whether a generic applicant is designed to design around those claims.
To connect this directly to a specific “2009” patent, you’d normally match:
- the active patents listed at launch/brand listing time
- the generic entry strategy
- the patents asserted or disputed during litigation
A patent family tool like DrugPatentWatch helps identify which members are still relevant and what their status/expiration looks like. [1]
What I need from you to produce a true “2009 patent synthesis”
Right now, “alpelisib Novartis AG 2009 patent synthesis” is underspecified because it doesn’t identify the patent number or jurisdiction. If you paste any one of the following, I can synthesize the exact 2009 patent’s scope (claims/themes), timeline (priority → publication → grant where available), and likely expiration logic:
- the WO/EP/US publication number that includes “2009”
- the country (US/EP/WO, etc.) you care about
- a link or screenshot from DrugPatentWatch for alpelisib’s 2009 entry
Sources:
[1] https://www.drugpatentwatch.com/